Podcasts about reachmd

  • 74PODCASTS
  • 13,722EPISODES
  • 38mAVG DURATION
  • 1DAILY NEW EPISODE
  • Sep 9, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about reachmd

Show all podcasts related to reachmd

Latest podcast episodes about reachmd

Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study

Project Oncology®

Play Episode Listen Later Sep 9, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustained 24-month progression-free survival in relapsed/refractory marginal zone lymphoma. Here with Dr. Charles Turck to share the key efficacy and safety findings is Dr. Sairah Ahmed, Professor in the Department of Lymphoma and Myeloma and CAR T Program Director at MD Anderson Cancer Center.

Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices

Project Oncology®

Play Episode Listen Later Sep 9, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Samuel Yamshon, MD The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as complementary strategies in combination with chemoimmunotherapy—they raise important questions around sequencing, durability, and patient selection. Joining Dr. Charles Turck to explore the real-world implications of this evolving approach is Dr. Samuel Yamshon, Director of the Cellular Therapy Service and an Assistant Professor of Medicine at Weill Cornell Medicine in New York.

Project Oncology®
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer

Project Oncology®

Play Episode Listen Later Sep 9, 2025


Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing

Project Oncology®

Play Episode Listen Later Sep 9, 2025


Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption

Project Oncology®

Play Episode Listen Later Sep 9, 2025


Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Project Oncology®
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care

Project Oncology®

Play Episode Listen Later Sep 9, 2025


Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Conference Coverage
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care

Conference Coverage

Play Episode Listen Later Sep 9, 2025


Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Conference Coverage
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption

Conference Coverage

Play Episode Listen Later Sep 9, 2025


Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Conference Coverage
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing

Conference Coverage

Play Episode Listen Later Sep 9, 2025


Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Conference Coverage
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer

Conference Coverage

Play Episode Listen Later Sep 9, 2025


Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Medical Industry Feature
Pioneering a First in Robotic Liver Transplant

Medical Industry Feature

Play Episode Listen Later Sep 8, 2025


Guest: Juan P. Rocca, M.D., MHA On this episode of Advances in Care, host Erin Welsh hears from Dr. Juan P. Rocca, a transplant surgeon at NewYork-Presbyterian and Weill Cornell Medicine who recently led the first fully robotic liver transplant in New York. Dr. Rocca details the recent developments in robotic surgery at Weill Cornell Medicine's Division of Liver Transplantation and Hepatobiliary Surgery, including an ongoing push to advance from laparoscopic and open surgical methods, and now to robotics. He explains why the robotic approach is optimal for complex liver surgeries and discusses how he and his team have been training to make robotic living donor hepatectomies a standard in their department. Then, Dr. Rocca breaks down the process of the liver transplant operation that became the first fully robotic execution in New York. He describes the most critical steps of the procedure, how it felt to achieve this milestone, and the example that he hopes to set for other institutions beyond NewYork-Presbyterian and Weill Cornell Medicine. © 2025 NewYork-Presbyterian

Advances in Women's Health
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer

Advances in Women's Health

Play Episode Listen Later Sep 4, 2025


Guest: Ann Klopp, M.D., Ph.D. The recent NRG0238 trial evaluated whether adding chemotherapy to radiation improves outcomes in patients with localized endometrial cancer recurrences. Hear from Dr. Ann Klopp as she explains the findings and how they could shift practice patterns for patient care. Dr. Klopp is a Professor of Radiation Oncology, the Director of Brachytherapy, and the leader of the gynecologic section in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Advances in Women's Health
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management

Advances in Women's Health

Play Episode Listen Later Sep 4, 2025


Guest: Ann Klopp, M.D., Ph.D. Endometrial cancer treatment is continuing to evolve, with surgery guiding initial decisions and new evidence showing that adding immunotherapy significantly improves outcomes in advanced disease. But key questions remain around tailoring regimens to individual patients. Dr. Ann Klopp highlights the latest advances and challenges in management, particularly in patients with pelvic recurrences. Dr. Klopp is a Professor of Radiation Oncology, the Director of Brachytherapy, and the leader of the gynecologic section at the University of Texas MD Anderson Cancer Center in Houston.

GI Insights
Reimagining GI Care: Digital Therapeutics for Managing IBS and IBD Symptoms

GI Insights

Play Episode Listen Later Sep 3, 2025


Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Iris Wang, M.D. From symptom trackers to multidisciplinary app-based platforms, evidence-based digital therapeutics are expanding access to brain-gut behavioral care for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Dr. Peter Buch sits down with Dr. Iris Wang to discuss the spectrum of available tools and explore strategies for aligning them with individual patient needs. Dr. Wang is an Associate Professor of Medicine and the Associate Program Director of the Gastroenterology Fellowship at the Mayo Clinic in Rochester, Minnesota.

GI Insights
Preventive Care Essentials for Patients with IBD: Reviewing ACG Guideline Updates

GI Insights

Play Episode Listen Later Sep 3, 2025


Guest: Francis Farraye, MD Host: Peter Buch, MD, FACG, AGAF, FACP A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author of this guideline, to highlight what clinicians need to know. Dr. Farraye is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida

GI Insights
Navigating Iron Deficiency Anemia: A Practical Guide for Gastroenterologists

GI Insights

Play Episode Listen Later Sep 3, 2025


Guest: Thomas DeLoughery, MD Host: Peter Buch, MD, FACG, AGAF, FACP Iron deficiency anemia is common in gastroenterology patients and is often underrecognized or suboptimally managed. That's why targeted treatment is essential to improve patient outcomes. In this expert-led discussion, Dr. Peter Buch and Dr. Thomas DeLoughery outline what gastroenterologists need to know about oral vs IV iron, absorption dynamics, and tailoring therapy for various patient populations. Dr. DeLoughery is a Professor of Medicine in the Division of Hematology and Oncology at Oregon Health and Science University in Portland.

ReachMD CME
Retina Case Review: Translating the Data Into Care

ReachMD CME

Play Episode Listen Later Sep 2, 2025


CME credits: 0.25 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Retina-Case-Review-Translating-the-Data-Into-Care/36108/ Wondering how your practice's use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits. =

The Art of Medicine with Dr. Andrew Wilner
Success in Solo Practice! an interview with physician coach Kara Pepper, MD

The Art of Medicine with Dr. Andrew Wilner

Play Episode Listen Later Aug 31, 2025 32:56


Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Kara Pepper, MD, for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Dr. Pepper is an internal medicine physician and former professional ballet dancer. After her residency in internal medicine, Dr. Pepper joined a corporate medical practice. Although she felt it wasn't the perfect fit, she stuck with it. After about seven years, she succumbed to burnout and left on sabbatical. She resumed her job but still wasn't satisfied. The stark reality of the COVID pandemic forced Kara to reassess her priorities. Three years ago, she left corporate medicine to create a solo practice. What began as a telemedicine practice now includes in-person visits as well. She specializes in treating patients with eating disorders. By running her own practice, Dr. Pepper feels she can better serve patients, especially those who feel marginalized by the health care system. Dr. Pepper also discovered a community of physicians who struck out on their own and developed satisfying and successful practices. She happily shares her experience as a physician coach with other doctors who are unhappy in medicine and considering solo practice. She emphasized that "physicians have a voice and autonomy…are not prisoners of their jobs, and can create something new." To learn more about creating a successful solo practice, check out her website: www.karapeppermd.com or contact Kara Pepper, MD: hello@karapeppermd.com  #AI #ambientscribe #locumtenens #solopractice #eatingdisorders #womenentrepreneurPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Project Oncology®
Expanding Cancer Detection: How MCED Testing Complements Standard Screening

Project Oncology®

Play Episode Listen Later Aug 29, 2025


Guest: Jennifer Caudle, DO Host: Patrick McGill, MD Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylation patterns to identify potential cancers earlier than traditional imaging. Designed for the general population over age 50, MCED testing complements rather than replaces standard screenings, helping detect cancers at stages when treatment is most effective. Joining Dr. Jennifer Caudle to share practical strategies for integrating MCED into clinical workflows, addressing misconceptions, and streamlining follow-up protocols is Dr. Patrick McGill, board-certified family physician and Executive Vice President, Chief Transformation Officer at Community Health Network in Indianapolis.

Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices

Project Oncology®

Play Episode Listen Later Aug 28, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Evandro Bezerra, MD As CAR T-cell therapy advances, so does the complexity of adverse event monitoring. Due to evolving insights into acute toxicities, infections, cytopenias, and secondary malignancies, both inpatient and outpatient care models are adapting to meet new standards. Joining Dr. Charles Turck to discuss practical strategies and emerging tools for managing post-CAR T toxicities across the continuum of care is Dr. Evandro Bezerra, Clinical Assistant Professor at Ohio State University Comprehensive Cancer Center in Columbus.

NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches

NeuroFrontiers

Play Episode Listen Later Aug 26, 2025


Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.

GI Insights
Managing Anticoagulants During Acute GI Bleeds: Guideline-Based Best Practices

GI Insights

Play Episode Listen Later Aug 25, 2025


Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Neena Abraham, MD, MS Knowing how to manage anticoagulants and antithrombotics during acute GI bleeding is essential in preventing avoidable complications, including thromboembolism and delayed hemostasis. Dr. Peter Buch sits down with Dr. Neena Abraham to discuss the latest recommendations from major GI and cardiology societies and explore practical strategies for anticoagulant reversal, triage criteria, and endoscopic hemostasis. Dr. Abraham is a Professor of Medicine and the Medical Director of the Cardiogastroenterology Clinic at the Mayo Clinic in Phoenix.

Project Oncology®
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing

Project Oncology®

Play Episode Listen Later Aug 25, 2025


Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.

Project Oncology®
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening

Project Oncology®

Play Episode Listen Later Aug 25, 2025


Host: Brian P. McDonough, MD, FAAFP Guest: Mylynda Massart, MD, PhD Given its ability to identify universal cancer signals across multiple tumor types, multi-cancer early detection (MCED) testing is emerging as a promising tool to complement traditional, single-cancer screening methods. Joining Dr. Brian McDonough to share practical strategies for introducing MCED testing into clinical workflows and enhancing patient engagement is Dr. Mylynda Massart. Not only is she an Associate Professor at the University of Pittsburgh School of Medicine, but she's also the Founder and Medical Director of the Primary Care Precision Medicine Clinic and Associate Director of Clinical Services for the Institute for Precision Medicine at the University of Pittsburgh Medical Center.

Project Oncology®
Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration

Project Oncology®

Play Episode Listen Later Aug 22, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Forat Lutfi, MD Guest: Nilanjan Ghosh, MD, PhD For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-cell therapy can be life-saving, but communication gaps between referring physicians and CAR T centers can lead to delays or missed opportunities. Fortunately, practical strategies like building strong referral networks, improving direct communication, and aligning on shared care responsibilities can streamline access and improve outcomes. Joining Dr. Charles Turck to share their insights on how we can bridge these communication gaps are Drs. Forat Lutfi and Nilanjan Ghosh. Dr. Lutfi is an Assistant Professor of Hematologic Malignancies and Cellular Therapeutics at University of Kansas Medical Center, and Dr. Ghosh is a Professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.

Medical Industry Feature
Fibrodysplasia Ossificans Progressiva: Mechanism of Disease

Medical Industry Feature

Play Episode Listen Later Aug 21, 2025


Fibrodysplasia ossificans progressiva (FOP) is a severely disabling myopathy in which extraskeletal bone forms and accumulates over time within muscles and soft tissues.1,2 Here's what we know so far about the mechanisms of heterotopic ossification in patients with FOP. References: Kaplan FS et al. Best Pract Res Clin Rheumatol 2008;22:191–205. Pignolo RJ et al. Orphanet J Rare Dis 2011;6:80. © 2025 Ipsen Biopharmaceuticals Inc. All rights reserved. ALLSC-US-001927 | August 2025

Advances in Women's Health
Optimizing Access to Endometriosis Treatment: Strategies for Timely, Effective Care

Advances in Women's Health

Play Episode Listen Later Aug 19, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jacqueline Wong, MD, MSCR, FACOG For patients with endometriosis, treatment delays can profoundly impact both quality of life and clinical outcomes. Proactive strategies that address logistical barriers—such as prior authorizations—combined with education and multidisciplinary support are essential in improving care. Join Dr. Charles Turck and Dr. Jacqueline Wong as they explore practical approaches for managing this complex condition and navigating potential hurdles. Dr. Wong is a minimally invasive gynecologic surgeon and an Assistant Professor of Obstetrics and Gynecology in the School of Medicine at Oregon Health and Science University in Portland.

Project Oncology®
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay

Project Oncology®

Play Episode Listen Later Aug 19, 2025


Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there's an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection. Reference: Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

The Art of Medicine with Dr. Andrew Wilner
AI in the Doctor's Office with Marvix.AI CoFounder Rashie Jain

The Art of Medicine with Dr. Andrew Wilner

Play Episode Listen Later Aug 17, 2025 41:07


Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Rashie Jain for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Rashie is an engineer and Co-Founder of Marvix.AI, her second start-up. Rashie observed that many physicians struggle with high administrative burdens, especially medical specialists who spend more time with patients and deal with complex cases. With the advent of large language models, she created an "ambient scribe" that takes notes during a patient encounter, organizes them, and presents them for review as a finished product. With just a little tweaking, doctors can embed these notes into the electronic medical record (EMR). I tried out Rashie's software at the recent American Academy of Neurology meeting in San Diego, CA. Her Co-Founder played the role of a migraine patient, and we chatted for about 10 minutes. Truth be told, the ambient scribe did a great job capturing the essential details. I could have edited it in just a couple of minutes, which would save time compared to typing it into the EMR myself! To learn more about Marvix.AI, or to try it in your own office, please contact Rashie Jain at https://www.marvixapp.ai#AI #ambientscribe #largelanguagemodel #womenentrepreneurPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Medical Industry Feature
QuickStart™ Myopia Minute: The Benefits, Comfort, and Safety of MiSight® 1 day

Medical Industry Feature

Play Episode Listen Later Aug 15, 2025


Guest: Eric Ritchey, OD, PhD, FAAO Listen to Dr. Eric Ritchey explain how he introduces MiSight® 1 day to parents—highlighting its safety, comfort, and dual benefits—and emphasizes the importance of daily disposables for hygiene and the long-term eye health advantages of managing myopia early in children.

Medical Industry Feature
QuickStart™ Myopia Minute: Talking to Parents About Treatment Options

Medical Industry Feature

Play Episode Listen Later Aug 15, 2025


Guest: Sheila Morrison, OD, MS, FSLS In this short video, Dr. Shelia Morrison explains how she introduces parents to myopia management by emphasizing that today's treatment options—like MiSight® 1 day—can both correct vision and slow myopia progression during critical growth periods. She highlights the importance of early intervention and presents daily disposable lenses as a safe, effective solution for active children.

Medical Industry Feature
QuickStart™ Myopia Minute: Overcoming Barriers in Parent Conversations

Medical Industry Feature

Play Episode Listen Later Aug 15, 2025


Guest: Ariel Cerenzie, OD, FAAO, FSLS Dr. Ariel Cerenzie shares quick tips on how she communicates the urgency of myopia progression to parents and introduces MiSight® 1 day as a proactive solution. She explains that the lenses not only correct vision but also therapeutically slow myopia progression, offering a meaningful way to protect a child's long-term eye health.

Medical Industry Feature
Adjuvanted vs High-Dose Influenza Vaccines: A Real-World Evidence Study

Medical Industry Feature

Play Episode Listen Later Aug 15, 2025


Host: Jennifer Caudle, DO Guest: Blen Girmay, MD Because standard-dose vaccines usually produce only modest immunogenic responses in people age 65 years and older, the Advisory Committee on Immunization Practices, as of June 2022, recommended this age group receive either an adjuvanted or higher-dose seasonal influenza vaccine.1,2,3 A pragmatic, head-to-head randomized study compared FLUAD and the high-dose influenza vaccine over the course of two influenza seasons.2 Joining Dr. Jennifer Caudle to discuss this study and its findings from the first season (2023-2024) is Dr. Blen Girmay, a Johns Hopkins fellowship-trained primary care geriatrician at Inova Health System in Fairfax, Virginia. References: Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813-823. Klein N. Oral presentation presented at: IDWeek 2024 Meeting; October 16-19, 2024. Los Angeles, CA. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024;73(5):1-25.

Medical Industry Feature
Immune Imprinting and Vaccines: Rethinking the First Exposure to Influenza

Medical Industry Feature

Play Episode Listen Later Aug 15, 2025


Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4 References: King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169 Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149 Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138 USA-CRP-24-0038 July 2025

Project Oncology®
Redefining Cancer Care with Functional Precision Medicine

Project Oncology®

Play Episode Listen Later Aug 14, 2025


Host: Matt Birnholz, MD Guest: Jim Foote, MBA Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to guide individualized treatment. Dr. Matt Birnholz sits down with Jim Foote, CEO of First Ascent Biomedical, to explore how this approach delivers clinically actionable insights for relapsed and resistant cancer and empowers oncologists with faster, more targeted decision making.

Advances in Women's Health
GLP-1 Baby Boom and Birth Control Failures: Why It's Time to Talk IUDs

Advances in Women's Health

Play Episode Listen Later Aug 13, 2025


Host: Jennifer Caudle, DO Guest: Johanna Finkle, MD, FACOG As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

Medical Industry Feature
QuickStart™ Myopia Minute: Myopia Control and Early Treatment

Medical Industry Feature

Play Episode Listen Later Aug 12, 2025


Guest: Ashley Tucker, OD, FAAO, FSLS, Dipl ABO In this short video, Dr. Ashley Tucker shares how she talks to parents about myopia management, emphasizing that myopia is more than just blurry vision; it's a progressive condition that can lead to serious eye health risks. She introduces MiSight® 1 day as a dual-purpose option that not only corrects vision, but also helps slow the progression of myopia in age-appropriate children.

ReachMD CME
Optimizing Acute Treatment in the Era of Breakthrough Attacks

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35988/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
How to Build A Multidisciplinary Team in HAE to Optimize Patient Care

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35993/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
Next-Generation Therapies for Long-Term Prophylactic Treatment of HAE

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35992/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
Emerging Therapies for Acute HAE: New Target, New Therapies

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
Challenges in the Management of Difficult-to-Treat HAE

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35990/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
Prophylaxis Reimagined: Overcoming Challenges in Long-Term HAE Management

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35989/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
Breakthrough Attacks: Why Prophylaxis Isn't Always Enough

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35987/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
From Theory to Practice: Real-World Challenges in Personalized HAE Care

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35986/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

ReachMD CME
The Personal Touch: Advancing Personalized Treatment in HAE

ReachMD CME

Play Episode Listen Later Aug 11, 2025


CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35985/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

Medical Industry Feature
Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma

Medical Industry Feature

Play Episode Listen Later Aug 11, 2025


Guest: Mateo Mejia Saldarriaga, M.D. Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days. © 2025 NewYork-Presbyterian

Project Oncology®
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma

Project Oncology®

Play Episode Listen Later Aug 7, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

The Art of Medicine with Dr. Andrew Wilner
Navigating multiple sclerosis with author and patient Brenda Snow

The Art of Medicine with Dr. Andrew Wilner

Play Episode Listen Later Aug 3, 2025 32:56


Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Brenda Snow for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Brenda is the Founder and CEO of Snow Companies, which helps engage patients with their healthcare services. Her own life-changing experience with a neurologic disorder, which she experienced as an "identity earthquake," triggered the creation of her business, "Snow Companies." Thirty years ago, Brenda suffered from unexplained symptoms including double vision, dragging her left foot, loss of bladder control, and strange fatigue. After initial misadventures with a couple of neurologists, she was accurately diagnosed with multiple sclerosis. Brenda eventually discovered a supportive medical team. She takes regular multiple sclerosis treatments, maintains a healthy lifestyle, and lives an active and successful life. Brenda started "Snow Companies" nearly 25 years ago. Now with over 400 employees, Snow Companies helps pharmaceutical companies engage with their patients. Brenda also hopes to help patients with her new book, "Diagnosed: The Essential Guide to Navigating the Patient's Journey." Brenda graciously offered to send a free, signed copy of her book to anyone who can't afford it. Just send her an email through her website: https://brendasnow.com #multiple sclerosis #womenentrepreneurs #entrepreneurs #authorPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

The Art of Medicine with Dr. Andrew Wilner
"If it Sounds Like a Quack"-new book by journalist Matt Holgotz-Hetling

The Art of Medicine with Dr. Andrew Wilner

Play Episode Listen Later Jul 20, 2025 55:37


Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Matt Holgotz-Hetling for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Matt is a journalist and author of "If it Sounds Like a Quack…" His prior book, "A Libertarian Walks into a Bear," received 4.5 stars on Amazon and more than 1,000 reviews. During COVID, Matt took an interest in two conflicting forces he observed in American society. On the one hand, public health officials were trying to protect the public by recommending masks and closing schools. On the other hand, many independent-minded Americans insisted on making their own decisions, often eschewing masks and social distancing.  Matt was intrigued by fringe practitioners offering cures for COVID, which included baking soda, bleach, lasers, and leeches. Many alternative medicine practitioners had faith in their "One True Cure." Of course, it was difficult to eliminate greed and exploitation as supporting motivations. Matt and I had an in-depth conversation for nearly an hour! It was a treat to speak with such an informed and thoughtful author. Matt's newest book, "The Ghost Lab," should be available shortly. You can find all of Matt's books on Amazon. To learn more, please check out Matt's website:https://www.matt-hongoltzhetling.com#concussion #CTE #traumatic brain injury #TBI Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...